Compare Adaptive Biotechnologies Corp (ADPT) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $54.21. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| ADPT | QCLN | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $68.47 |
52-Week Low | $10.24 | $34.04 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
QCLN trades at $58.70, up 3.51% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces mixed sentiment amid clean energy sector volatility, with support at $55 and resistance at $60. Recent news highlights policy risks from stalled US permits and geopolitical tensions affecting solar supply chains, while global investment in renewables continues to grow.
Outlook remains cautious due to regulatory headwinds and cost pressures, though long-term clean energy demand provides upside potential. Key risks include US-China trade policies and inflation-driven installation costs, with investor sentiment divided between near-term challenges and structural growth opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
